Literature DB >> 8159031

Segmentectomy versus lobectomy in patients with stage I pulmonary carcinoma. Five-year survival and patterns of intrathoracic recurrence.

W H Warren1, L P Faber.   

Abstract

One hundred seventy-three patients with stage I (T1 N0, T2 N0) non-small-cell lung cancer underwent either a segmental pulmonary resection (n = 68) or lobectomy (n = 105) from 1980 to 1988. Four patients were lost to follow-up, but the remaining 169 patients were followed up for 5 years. Survival and the prevalence of local/regional recurrence were assessed. Although no survival advantage of lobectomy over segmental resection was noted for patients with tumors 3.0 cm in diameter or smaller, a survival advantage was apparent for patients undergoing lobectomy for tumors larger than 3.0 cm. The rate of local/regional recurrence was 22.7% (15/66) after segmental resection versus 4.9% (5/103) after lobectomy. A review of histologic tumor type, original tumor diameter, and segment resected revealed no risk factors that were predictive of recurrence. An additional resection for recurrence was performed in four patients. Lobectomy is the preferred operative procedure for patients with stage I tumors larger than 3.0 cm. Because the rate of local/regional recurrence was high after segmental resections, diligent follow-up of these patients is mandatory.

Entities:  

Mesh:

Year:  1994        PMID: 8159031

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  46 in total

1.  BTS guidelines: guidelines on the selection of patients with lung cancer for surgery.

Authors: 
Journal:  Thorax       Date:  2001-02       Impact factor: 9.139

2.  Clinical implications of the margin cytology findings and margin/tumor size ratio in patients who underwent pulmonary excision for peripheral non-small cell lung cancer.

Authors:  Noriyoshi Sawabata; Hajime Maeda; Akihide Matsumura; Mitsunori Ohta; Meinoshin Okumura
Journal:  Surg Today       Date:  2011-11-10       Impact factor: 2.549

Review 3.  Lung cancer. 6: The case for limited surgical resection in non-small cell lung cancer.

Authors:  D J Sugarbaker
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

4.  Limited resection for early-stage lung cancer.

Authors:  Tarek Mekhail; Joseph Boyer
Journal:  Curr Oncol Rep       Date:  2010-09       Impact factor: 5.075

5.  Dosimetric characterization of the GammaClip™ 169Yb low dose rate permanent implant brachytherapy source for the treatment of nonsmall cell lung cancer postwedge resection.

Authors:  Blake Currier; John J Munro; David C Medich
Journal:  Med Phys       Date:  2013-08       Impact factor: 4.071

6.  Anatomic segmental resection of the lung by thoracoscopy: an experimental study.

Authors:  K Koizumi; T Akaishi; A Wakabayashi
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

7.  Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer.

Authors:  Hiran C Fernando; Rodney J Landreneau; Sumithra J Mandrekar; Francis C Nichols; Shauna L Hillman; Dwight E Heron; Bryan F Meyers; Thomas A DiPetrillo; David R Jones; Sandra L Starnes; Angelina D Tan; Benedict D T Daly; Joe B Putnam
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

8.  Outcomes: wedge resection versus lobectomy for non-small cell lung cancer at the Cancer Centre of Southeastern Ontario 1998-2009.

Authors:  Anna L McGuire; Wilma M Hopman; Dimitri Petsikas; Ken Reid
Journal:  Can J Surg       Date:  2013-12       Impact factor: 2.089

9.  Video-assisted thoracoscopic lobectomy for non-small cell lung cancer in patients with severe chronic obstructive pulmonary disease.

Authors:  Wei Wang; Zhiqiang Xu; Xinguo Xiong; Weiqiang Yin; Xin Xu; Wenlong Shao; Hanzhang Chen; Jianxing He
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

10.  Ten-year follow-up of a province-wide cohort of surgical lung cancer patients in Nova Scotia.

Authors:  Daniel R Wong; Harry J Henteleff
Journal:  Can J Surg       Date:  2008-08       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.